Riverhead Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Riverhead Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$312K	Hold	5,024	–	–	0.01%	927
2019 Q2	$358K	Buy	5,024 +481	+11%	+$35.4K	0.01%	881
2019 Q1	$356K	Hold	4,543	–	–	0.01%	862
2018 Q4	$385K	Hold	4,543	–	–	0.02%	756
2018 Q3	$778K	Hold	4,543	–	–	0.03%	570
2018 Q2	$587K	Hold	4,543	–	–	0.02%	627
2018 Q1	$468K	Hold	4,543	–	–	0.02%	686
2017 Q4	$388K	Buy	4,543 +962	+27%	+$83.4K	0.02%	766
2017 Q3	$304K	Buy	3,581 +699	+24%	+$55.3K	0.01%	798
2017 Q2	$218K	Buy	2,882 +1,439	+100%	+$101K	0.01%	880
2017 Q1	$95K	Buy	1,443 +161	+13%	+$10.6K	0.01%	1026
2016 Q4	$81K	Hold	1,282	–	–	0.01%	1057
2016 Q3	$82K	Sell	1,282 -23,263	-95%	-$1.71M	0.01%	993
2016 Q2	$608K	Buy	24,545 +19,467	+383%	+$1.44M	0.02%	560
2016 Q1	$340K	Sell	5,078 -693	-12%	-$42.1K	﹤0.01%	1061
2015 Q4	$390K	Buy	5,771 +4,008	+227%	+$247K	0.01%	1019
2015 Q3	$94K	Buy	+1,763	New	+$107K	﹤0.01%	1126

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Riverhead Capital Management's LGND Position: Q3 2019 in Review

Riverhead Capital Management held its Ligand Pharmaceuticals (LGND) position steady in Q3 2019 at 5,024 shares worth $312K. The position accounts for 0.01% of the portfolio, ranked #927.

Riverhead Capital Management first reported a position in LGND in Q3 2015 and has held it in 17 quarters since. The position peaked at $778K in Q3 2018. 275 funds tracked by Wall St. Rank hold LGND as of Q3 2019.

Riverhead Capital Management held 5,024 shares of Ligand Pharmaceuticals worth $312K as of Q3 2019.
Riverhead Capital Management left its Ligand Pharmaceuticals share count unchanged in Q3 2019.
Ligand Pharmaceuticals made up 0.01% of Riverhead Capital Management's portfolio in Q3 2019, its #927 holding.
Riverhead Capital Management first reported a position in Ligand Pharmaceuticals in Q3 2015 and has held it in 17 quarters since.
Riverhead Capital Management's Ligand Pharmaceuticals position peaked at $778K in Q3 2018.
275 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.